The Lymphoma Research Foundation is aware that the supply of the vital chemotherapy medicine vincristine [Oncovin] may be limited in certain areas of the country. We understand this news is very concerning to patients who receive this medicine and their…
Lymphoma Research Foundation’s Premier Light it Red for Lymphoma Initiative Expected to Reach Millions during Blood Cancer Awareness Month The Lymphoma Research Foundation (LRF) announced its annual international Light it Red for Lymphoma awareness initiative. Since 2011, the Foundation has…
Lymphoma Research Foundation Chief Executive Officer Meghan Gutierrez was recognized as a leader in healthcare by both Crain’s New York Business and PR News. Gutierrez was among 100 women listed in Crain’s Notable Women in Health Care 2019, recognizing her…
The U.S. Food and Drug Administration (FDA) requested the voluntary recall from Allergan in reference to the company’s Biocell textured implants linked to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). According to the Agency, Allergan agreed and is removing these…
On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab (Rituxan, Genentech, Biogen) for the treatment of CD20-positive non-Hodgkin B-cell Lymphoma (NHL) and chronic lymphocytic…
Several oral agents have been proven active in the treatment of certain subtypes of non-Hodgkin lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and Waldentröm macroglobulinemia (WM); and for…